FDA Approves Brexucabtagene Autoleucel for B-Cell Precursor Acute Lymphoblastic Leukemia
October 4th 2021A single infusion of the CAR T-cell therapy Tecartus produced a high and durable response rate in heavily pretreated patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Read More
Study: Medications, Surgery May Help Obesity-Related High Blood Pressure in Lieu of Diet, Exercise
October 1st 2021The national guidelines recommend a heart-healthy diet to help manage weight and control blood pressure, while also emphasizing dietary patterns rather than individual foods and nutrients.
Read More
The Impact of the FDA's Project Optimus on Oncology Drug Trials
October 1st 2021In an interview with Pharmacy Times®, Maria Whitman, Global Head of the Pharmaceutical and Biotech Practice at ZS, discusses the FDA’s Project Optimus, the FDA’s new guidance addressing dose optimization issues in oncology clinical trials, and how it has impacted drug manufacturers.
Watch
Pharmacy Focus Episode 32: Highlights in Treatment of Cervical Cancer
October 1st 2021The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.
Listen
How to Adopt USP Labeling Standards to Increase Health Equity
September 30th 2021Donna Bohannon, RPh, MS, principal scientist at US Pharmacopeia (USP), and Bhumi Khambholja, PharmD, MSHI, project manager of Wisconsin Health Literacy, discuss how to adopt USP standards for labeling to increase health equity.
Watch
Study: Most Blood Cancer Patients Could Benefit From Additional Dose of COVID-19 Vaccine
September 30th 2021Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.
Read More
The Changing Landscape of Relapsed/Refractory Chronic Lymphocytic Leukemia Treatment
September 30th 2021Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.
Read More